An overview of current and future treatment methods for lupus nephritis

Bibliography

• Jakes RW, Bae SC, Louthrenoo W, et al. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken) 2012;64:159-68
   PubMed Web of Science ®Google Scholar
• Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol 2010;21:2028-35
   PubMed Web of Science ®Google Scholar
• Saxena R, Mahajan T, Mohan C. Lupus nephritis: current update. Arthritis Res Ther 2011;13:240
   PubMed Web of Science ®Google Scholar
• Yap DY, Tang CS, Ma MK, et al. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant 2012;27:3248-54
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Schwartz MM, Korbet SM, et al. Lupus nephritis. 2nd edition. Oxford University Press, Oxford; 2010
   Google Scholar
• Donadio JV Jr, Holley KE, Ferguson RH, et al. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978;299:1151-5
   PubMed Web of Science ®Google Scholar
• Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-19
   PubMed Web of Science ®Google Scholar
• Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945-50
   PubMed Web of Science ®Google Scholar
• Gourley MF, Austin HA III, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996;125:549-57
   PubMed Web of Science ®Google Scholar
• Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57
   PubMed Web of Science ®Google Scholar
• Yap DY, Ma MK, Tang CS, et al. Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience. Nephrology (Carlton) 2012;17:676-80
   PubMed Web of Science ®Google Scholar
• Wang HY, Cui TG, Hou FF, et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 2008;17:638-44
   PubMed Web of Science ®Google Scholar
• Tanaka H, Tsugawa K, Oki E, et al. Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patients. Clin Rheumatol 2008;27:85-9
   PubMed Web of Science ®Google Scholar
• Bao H, Liu ZH, Xie HL, et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 2008;19:2001-10
   PubMed Web of Science ®Google Scholar
• Tse KC, Lam MF, Tang SC, et al. A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus 2007;16:46-51
   PubMedGoogle Scholar
• Tse KC, Li FK, Tang S, et al. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus 2005;14:947-52
   PubMedGoogle Scholar
• Tanaka H, Watanabe S, Aizawa-Yashiro T, et al. Long-term tacrolimus-based immunosuppressive treatment for young patients with lupus nephritis: a prospective study in daily clinical practice. Nephron Clin Pract 2013;121:c165-c73
   Google Scholar
• Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012;64:797-808
   PubMed Web of Science ®Google Scholar
• Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771-82
   PubMed Web of Science ®Google Scholar
• Kidney Disease: improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guidelines for glomerulonephritis. Kidney Int Suppl 2012;2:139-274
   Web of Science ®Google Scholar
• Mok CC, Yap DY, Navarra SV, et al. Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology (Carlton) 2013. [Epub ahead of print]
   Google Scholar
• Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford) 2012;51:1145-53
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31
   PubMed Web of Science ®Google Scholar
• Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28
   PubMed Web of Science ®Google Scholar
• Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum 2003;32:370-7
   PubMed Web of Science ®Google Scholar
• Kong KO, Badsha H, Lian TY, et al. Low-dose pulse methylprednisolone is an effective therapy for severe SLE flares. Lupus 2004;13:212-13
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Austin HA III, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Lan SP, et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992;326:1373-9
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010;69:61-4
   PubMed Web of Science ®Google Scholar
• Bakir AA, Levy PS, Dunea G. The prognosis of lupus nephritis in African-Americans: a retrospective analysis. Am J Kidney Dis 1994;24:159-71
   PubMed Web of Science ®Google Scholar
• Austin HA III, Boumpas DT, Vaughan EM, et al. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995;10:1620-8
   PubMed Web of Science ®Google Scholar
• Korbet SM, Schwartz MM, Evans J, et al. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007;18:244-54
   PubMed Web of Science ®Google Scholar
• Chan TM, Li FK, Wong RW, et al. Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron 1995;71:321-7
   PubMedGoogle Scholar
• Chan TM, Tse KC, Tang CS, et al. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005;14:265-72
   PubMed Web of Science ®Google Scholar
• Mok CC, Ho CT, Chan KW, et al. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 2002;46:1003-13
   PubMed Web of Science ®Google Scholar
• Mok CC, Ho CT, Siu YP, et al. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 2001;38:256-64
   PubMed Web of Science ®Google Scholar
• Mok CC, Ying KY, Tang S, et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004;50:2559-68
   PubMed Web of Science ®Google Scholar
• Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998;41:831-7
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancy in systemic lupus erythematosus: what have we learned? Best Pract Res Clin Rheumatol 2009;23:539-47
   PubMedGoogle Scholar
• Mok CC, Ying KY, Ng WL, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006;119:355. e25-33
   PubMed Web of Science ®Google Scholar
• Chan TM, Li FK, Hao WK, et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus 1999;8:545-51
   PubMed Web of Science ®Google Scholar
• Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006;70:732-42
   PubMed Web of Science ®Google Scholar
• Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010;69:2083-9
   PubMed Web of Science ®Google Scholar
• Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886-95
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993;136:5-28
   PubMed Web of Science ®Google Scholar
• Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-62
   PubMed Web of Science ®Google Scholar
• Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12
   PubMed Web of Science ®Google Scholar
• Mak SK, Lo KY, Lo MW, et al. Efficacy of enteric-coated mycophenolate sodium in patients with active lupus nephritis. Nephrology (Carlton) 2008;13:331-6
   PubMedGoogle Scholar
• Zeher M, Doria A, Lan J, et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus 2011;20:1484-93
   PubMed Web of Science ®Google Scholar
• Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010;49:128-40
   PubMed Web of Science ®Google Scholar
• Korbet SM, Lewis EJ, Schwartz MM, et al. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000;35:904-14
   PubMed Web of Science ®Google Scholar
• Yap DY, Ma MK, Mok MM, et al. Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis. Rheumatology (Oxford) 2013;52:480-6
   PubMed Web of Science ®Google Scholar
• Tse KC, Tang CS, Lio WI, et al. Quality of life comparison between corticosteroid- and-mycofenolate mofetil and corticosteroid- and-oral cyclophosphamide in the treatment of severe lupus nephritis. Lupus 2006;15:371-9
   PubMed Web of Science ®Google Scholar
• Tse KC, Tang CS, Lam MF, et al. Cost comparison between mycophenolate mofetil and cyclophosphamide-azathioprine in the treatment of lupus nephritis. J Rheumatol 2009;36:76-81
   PubMedGoogle Scholar
• Chan TM, Tse KC, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-84
   PubMed Web of Science ®Google Scholar
• Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995;60:225-32
   PubMed Web of Science ®Google Scholar
• Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995;345:1321-5
   PubMed Web of Science ®Google Scholar
• Spetie DN, Tang Y, Rovin BH, et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 2004;66:2411-15
   PubMed Web of Science ®Google Scholar
• Yap DY, Yu X, Chen XM, et al. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology (Carlton) 2012;17:352-7
   PubMedGoogle Scholar
• Radhakrishnan J, Moutzouris DA, Ginzler EM, et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010;77:152-60
   PubMed Web of Science ®Google Scholar
• Zavada J, Pesickova S, Rysava R, et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus 2010;19:1281-9
   PubMed Web of Science ®Google Scholar
• Tanaka H, Oki E, Tsuruga K, et al. Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose. Clin Nephrol 2009;72:430-6
   PubMedGoogle Scholar
• Moroni G, Doria A, Mosca M, et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 2006;1:925-32
   PubMed Web of Science ®Google Scholar
• Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis 2011;57:235-44
   PubMed Web of Science ®Google Scholar
• Li X, Ren H, Zhang Q, et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant 2012;27:1467-72
   PubMed Web of Science ®Google Scholar
• Bensman A, Niaudet P. Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies. Pediatr Nephrol 2010;25:1197-9
   PubMedGoogle Scholar
• Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008;14:931-8
   PubMed Web of Science ®Google Scholar
• Austin HA III, Illei GG, Braun MJ, et al. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009;20:901-11
   PubMed Web of Science ®Google Scholar
• Szeto CC, Kwan BC, Lai FM, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford) 2008;47:1678-81
   PubMed Web of Science ®Google Scholar
• Margreiter R, European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002;359:741-6
   PubMed Web of Science ®Google Scholar
• Nankivell BJ, Chapman JR, Bonovas G, et al. Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. Transplantation 2004;77:1457-9
   PubMedGoogle Scholar
• Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002;73:775-82
   PubMed Web of Science ®Google Scholar
• Diekmann F, Campistol JM. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant 2006;21:562-8
   PubMed Web of Science ®Google Scholar
• Gabardi S, Baroletti SA. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy 2010;30:1044-56
   PubMed Web of Science ®Google Scholar
• Lui SL, Tsang R, Chan KW, et al. Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice. Nephrol Dial Transplant 2008;23:2768-76
   PubMed Web of Science ®Google Scholar
• Lui SL, Yung S, Tsang R, et al. Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice. Lupus 2008;17:305-13
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 2012;64:1215-26
   PubMed Web of Science ®Google Scholar
• Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280-6
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31
   PubMed Web of Science ®Google Scholar
• Dooley M, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013;22:63-72
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30
   PubMed Web of Science ®Google Scholar
• Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 2012;64:3660-5
   PubMed Web of Science ®Google Scholar
• Pepper R, Griffith M, Kirwan C, et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009;24:3717-23
   PubMed Web of Science ®Google Scholar
• Weidenbusch M, Rommele C, Schrottle A, et al. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 2013;28:106-11
   PubMed Web of Science ®Google Scholar
• Kraft SW, Schwartz MM, Korbet SM, et al. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol 2005;16:175-9
   PubMed Web of Science ®Google Scholar
• Rovin BH, Parikh SV, Hebert LA, et al. Lupus nephritis: induction therapy in severe lupus nephritis–should MMF be considered the drug of choice? Clin J Am Soc Nephrol 2013;8:147-53
   PubMed Web of Science ®Google Scholar
• Punyawudho B, Lertdumrongluk P, Somparn P, et al. Population pharmacokinetics of mycophenolate mofetil in Thai lupus nephritis patients. Int J Clin Pharmacol Ther 2012;50:272-80
   PubMed Web of Science ®Google Scholar
• Lertdumrongluk P, Somparn P, Kittanamongkolchai W, et al. Pharmacokinetics of mycophenolic acid in severe lupus nephritis. Kidney Int 2010;78:389-95
   PubMed Web of Science ®Google Scholar
• Chan TM. Preventing renal failure in patients with severe lupus nephritis. Kidney Int Suppl 2005;S116-19
   Google Scholar
• Sloan RP, Schwartz MM, Korbet SM, et al. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group. J Am Soc Nephrol 1996;7:299-305
   PubMed Web of Science ®Google Scholar
• Honkanen E, Tornroth T, Gronhagen-Riska C, et al. Long-term survival in idiopathic membranous glomerulonephritis: can the course be clinically predicted? Clin Nephrol 1994;41:127-34
   PubMedGoogle Scholar
• Mercadal L, Montcel ST, Nochy D, et al. Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol Dial Transplant 2002;17:1771-8
   PubMed Web of Science ®Google Scholar
• Mok CC, Ying KY, Lau CS, et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. Am J Kidney Dis 2004;43:269-76
   PubMed Web of Science ®Google Scholar
• Swan JT, Riche DM, Riche KD, et al. Systematic review and meta-analysis of immunosuppressant therapy clinical trials in membranous lupus nephritis. J Investig Med 2011;59:246-58
   PubMedGoogle Scholar
• Furie RA, Looney RJ, Rovin BH. Efficacy and safety of rituximab in patients with proliferative lupus nephritis: results from the randomized, double-blinded phase III LUNAR study. Ann Rheum Dis 2010;69(Suppl 3):549a
   Google Scholar